FDA to Review Topical PDE4-Inhibitor Roflumilast for Psoriasis

In an open label phase 2b study of roflumilast, the treatment effect lasted for 52-64 weeks, according to the manufacturer.
Medscape Medical News

source https://www.medscape.com/viewarticle/965801?src=rss